Tempest Therapeutics (NASDAQ:TPST) Releases Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Tempest Therapeutics (NASDAQ:TPST) posted its quarterly earnings results on Thursday. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.04), FiscalAI reports.

Tempest Therapeutics Stock Performance

Shares of TPST traded down $0.04 during mid-day trading on Thursday, hitting $1.17. 277,052 shares of the company traded hands, compared to its average volume of 182,246. Tempest Therapeutics has a 1 year low of $0.84 and a 1 year high of $12.23. The stock has a 50-day moving average price of $1.07 and a two-hundred day moving average price of $1.72. The stock has a market cap of $18.70 million, a price-to-earnings ratio of -0.19 and a beta of -1.72.

Analyst Ratings Changes

TPST has been the subject of a number of analyst reports. Zacks Research lowered shares of Tempest Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Wall Street Zen downgraded shares of Tempest Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tempest Therapeutics in a research report on Monday, July 13th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Reduce”.

Institutional Investors Weigh In On Tempest Therapeutics

A hedge fund recently raised its stake in Tempest Therapeutics stock. Vanguard Group Inc. raised its holdings in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) by 20.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 162,560 shares of the company’s stock after buying an additional 27,952 shares during the period. Vanguard Group Inc. owned about 3.66% of Tempest Therapeutics worth $1,671,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 22.52% of the company’s stock.

Tempest Therapeutics Company Profile

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.